MedTrace Logo

Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma

NCT00901927 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2020-04-03

Study results available
· View outcomes & findings →

Summary

The goal of this clinical research study is to learn if the combination of bendamustine hydrochloride, mitoxantrone, and rituximab can help to control follicular lymphoma.

The safety of this drug combination will also be studied.

Conditions

Interventions

DRUG

Bendamustine

Starting dose 90 mg/m\^2 by vein over 30-60 minutes on Days 1 and 2 of each cycle.

DRUG

Mitoxantrone

10 mg/m\^2 by vein over 15 minutes on Day 2 of each cycle.

DRUG

Rituximab

375 mg/m\^2 by vein over several hours on Day 1 of each cycle.

Sponsors & Collaborators

  • Cephalon

    collaborator INDUSTRY

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Nathan Fowler, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2016-01-31
Completion
2016-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00901927 on ClinicalTrials.gov